Study Phase II, open-label, randomized, bevacizumab, cisplatin and pemetrexed as first-line treatment of patients with non-small cell lung cancer (NSCLC) and squamous, stage IIIB - with pleural / pericardial malignant - or IV

Trial Profile

Study Phase II, open-label, randomized, bevacizumab, cisplatin and pemetrexed as first-line treatment of patients with non-small cell lung cancer (NSCLC) and squamous, stage IIIB - with pleural / pericardial malignant - or IV

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Status changed from recruiting to completed, based on final results presented in abstract at ASCO 2015.
    • 02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 30 Oct 2012 Planned End Date added 21 Jan 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top